Evidence map›Paper›PMID 37908720›Full record

ArticleTheranostics2023

Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.

Yujie Sun, Yanxia Guo, Xiaoqing Liu, Jinling Liu, Honglai Sun, Zhongying Li, Min Wen, Sheng-Nan Jiang, Wenzhi Tan, Jin Hai Zheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yujie SunSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Yanxia GuoSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Xiaoqing LiuSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Jinling LiuSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Honglai SunSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Zhongying LiSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Min WenDepartment of Neurosurgery, Guangzhou First People's Hospital, Guangzhou 510180, China.
Sheng-Nan JiangDepartment of Nuclear Medicine, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
Wenzhi TanSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Jin Hai ZhengSchool of Biomedical Science, Hunan University, Changsha 410082, China.
Hunan University · CNChangsha University of Science and Technology · CNGuangzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsAnimalsImmunotherapyMiceSalmonella typhimuriumTumor Microenvironmentbacterial-mediated cancer therapyclinical translationSalmonella typhimuriumsystemic safetyVNP20009

Identifiers

PMID37908720
PMCPMC10614684
OpenAlexW4388026421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.